Department of Pharmacy, Hospital Universitari del Mar, Barcelona. Spain..
Department of Medical Oncology, Hospital Universitari del Mar, Barcelona. Spain. Hospital del Mar Research Insitute (IMIM), Barcelona. Spain. Universitat Autónoma de Barcelona, Barcelona. Spain..
Farm Hosp. 2020 Nov 14;45(1):41-44. doi: 10.7399/fh.11460.
To present a new dexamethasone mouthwash formulation and analyze its effectiveness and safety among patients receiving stomatitis-producing antineoplastic agents.
Prospective observational study conducted in a university hospital between March 2017 and November 2019. Consecutive patients starting everolimus were enrolled. Patients were instructed to rinse dexamethasone mouthwash formulation twice daily until discontinuation of everolimus. A second cohort of patients with existing stomatitis induced by high probability of producing stomatitis chemotherapy therapies was also recruited to assess treatment effectiveness. Effectiveness and safety of dexamethasone mouthwash formulation was assessed.
Dexamethasone mouthwash formulation was prescribed in nine patients as prophylaxis. Six patients were diagnosed with breast cancer, two with neuroendocrine tumor and one with renal cell carcinoma. Four patients developed mild stomatitis (grade 1-2) and three patients discontinued everolimus due to other treatment-related adverse events. In addition, dexamethasone mouthwash formulation was prescribed as treatment in five patients with existing stomatitis. All patients achieved a significant reduction in the severity of stomatitis after starting the dexamethasone mouthwash formulation. In both cohorts, dexamethasone mouthwash formulation was well tolerated and neither dose reduction nor discontinuation related to stomatitis was required.
Dexamethasone mouthwash formulation could be considered as a suitable alternative for stomatitis management.
介绍一种新的地塞米松漱口液配方，并分析其在接受致口腔炎抗肿瘤药物治疗的患者中的疗效和安全性。
这是一项在 2017 年 3 月至 2019 年 11 月期间在一所大学医院进行的前瞻性观察性研究。连续入组开始服用依维莫司的患者。指导患者每天用地塞米松漱口液漱口两次，直至停用依维莫司。还招募了另一组因高概率引起口腔炎的化疗药物而存在口腔炎的患者，以评估治疗效果。评估了地塞米松漱口液配方的疗效和安全性。
九名患者预防性使用地塞米松漱口液。六名患者诊断为乳腺癌，两名为神经内分泌肿瘤，一名为肾细胞癌。四名患者出现轻度口腔炎（1-2 级），三名患者因其他治疗相关不良事件而停用依维莫司。此外，五名存在口腔炎的患者使用地塞米松漱口液作为治疗药物。所有患者在开始使用地塞米松漱口液后，口腔炎的严重程度均显著减轻。在两个队列中，地塞米松漱口液均耐受良好，均无需因口腔炎而减少剂量或停药。
地塞米松漱口液可作为口腔炎管理的一种合适选择。
